Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Effects of Genetics Variants of Pregnant Xenobiotic Receptor and on Pharmacogenetics and Drug Metabolism

Progress in research of cytochrome P450 3A4 gene polymorphism

Role of pregnane X receptor in chemotherapeutic treatment

The transcriptional regulation of drug enzymes and transporters mediated by Pregnane X receptor and its significant role in multidrug resistance

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Nuclear Receptors PXR and CAR: Implications for Drug Metabolism Regulation, Pharmacogenomics and Beyond

Regulation of Pregnane X Receptor(PXR)by Herbal Medicines

Biology of Pxr: Role in Drug-Hormone Interactions

Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance

Dietary phytochemicals as modulators of human pregnane X receptor

PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers

Function of pregnane X receptor in drug mechanism and research progress

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Advances in regulation of pregnane X receptor-mediated drug transporter

Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes

Genetic Polymorphisms in PXR and NF-κB1 Influence Susceptibility to Anti-Tuberculosis Drug-Induced Liver Injury.

Genetic Polymorphism of Cytochrome P450 and Drug Metabolism

Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study.

The role of pregnane X receptor (PXR) in substance metabolism

A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese.

Advances in Search for Pregnane X Receptor